2023-2028 Colombia Virology, Bacteriology, Parasitology and Mycology Testing Market-Growth Opportunities, 2023 Supplier Shares by Test, 2023-2028 Centralized and POC Volume and Sales Forecasts for 100 Respiratory, STD, Enteric, and other Microbiology Assays-Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks
This unique report from LeadingMarketResearch.com provides information not available from any other source, including test volume and sales forecasts for 100 individual tests, and competitor strategies. The report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the infectious disease testing market during the next five years.
The report is available by section, and can be customized to specific information needs and budget. The report reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Current and Emerging Products
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
The report is available by section, and can be customized to specific information needs and budget. The report reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Current and Emerging Products
- In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.
- Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.
- Companies developing or marketing infectious disease diagnostic products by individual test.
- Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
I. INTRODUCTION
II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Major Infectious Disease Tests
1. AIDS
2. Adenovirus
3. Aeromonads
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Chagas Disease
13. Chancroid
14. Chlamydia
15. Clostridium Difficile
16. Coronaviruses
17. Coxsackieviruses
18. Creutzfeldt-Jakob’s Disease
19. Cryptosporidium Parvum
20. Cyclospora Cayetanensis
21. Cytomegalovirus
22. Ebola Virus
23. E. Coli
24. Echovirus
25. Encephalitis
26. Enteroviruses
27. Epstein-Barr Virus
28. Giardia Lamblia
29. Gonorrhea
30. Granuloma Inguinale
31. Hantavirus
32. Helicobacter Pylori
33. Hepatitis
34. Herpes Simplex Virus
35. Human Herpes Virus-6 (HHV-6)
36. Influenza Viruses
37. Legionella
39. Lymphogranuloma Venereum (LGV)
40. Malaria
41. Measles (Rubeola)
42. Meningitis
43. Microsporidium
44. Mononucleosis
45. Mumps
46. Mycoplasma
47. Papillomaviruses
48. Parvovirus B19
49. Pneumonia
50. Polyomaviruses
51. Pseudomonas Aeruginosa
52. Rabies
53. Respiratory Syncytial Virus (RSV)
54. Rhinoviruses
55. Rotavirus (REOVIRUS)
56. Rubella (MEASLES)
57. Salmonellosis
58. Septicemia
59. Shigellosis
60. Staphylococcus Aureus
61. Streptococci
62. Syphilis
63. Toxoplasmosis
64. Trichomonas Vaginalis
65. Tuberculosis
66. Vibrio
67. West Nile Virus
68. Yersina
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Automated and Semi-automated Analyzers
C. Emerging Diagnostic Technologies
III. MARKET SIZE, GROWTH AND SALES FORECASTS BY TEST
IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
VI. ALTERNATIVE MARKET PENETRATION STRATEGIES
VII. DISTRIBUTION STRATEGIES FOR DECENTRALIZED TESTING MARKETS
VIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
IX. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujifilm Wako
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
QuidelOrtho
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher
II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Major Infectious Disease Tests
1. AIDS
2. Adenovirus
3. Aeromonads
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Chagas Disease
13. Chancroid
14. Chlamydia
15. Clostridium Difficile
16. Coronaviruses
17. Coxsackieviruses
18. Creutzfeldt-Jakob’s Disease
19. Cryptosporidium Parvum
20. Cyclospora Cayetanensis
21. Cytomegalovirus
22. Ebola Virus
23. E. Coli
24. Echovirus
25. Encephalitis
26. Enteroviruses
27. Epstein-Barr Virus
28. Giardia Lamblia
29. Gonorrhea
30. Granuloma Inguinale
31. Hantavirus
32. Helicobacter Pylori
33. Hepatitis
34. Herpes Simplex Virus
35. Human Herpes Virus-6 (HHV-6)
36. Influenza Viruses
37. Legionella
39. Lymphogranuloma Venereum (LGV)
40. Malaria
41. Measles (Rubeola)
42. Meningitis
43. Microsporidium
44. Mononucleosis
45. Mumps
46. Mycoplasma
47. Papillomaviruses
48. Parvovirus B19
49. Pneumonia
50. Polyomaviruses
51. Pseudomonas Aeruginosa
52. Rabies
53. Respiratory Syncytial Virus (RSV)
54. Rhinoviruses
55. Rotavirus (REOVIRUS)
56. Rubella (MEASLES)
57. Salmonellosis
58. Septicemia
59. Shigellosis
60. Staphylococcus Aureus
61. Streptococci
62. Syphilis
63. Toxoplasmosis
64. Trichomonas Vaginalis
65. Tuberculosis
66. Vibrio
67. West Nile Virus
68. Yersina
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Automated and Semi-automated Analyzers
C. Emerging Diagnostic Technologies
III. MARKET SIZE, GROWTH AND SALES FORECASTS BY TEST
IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
VI. ALTERNATIVE MARKET PENETRATION STRATEGIES
VII. DISTRIBUTION STRATEGIES FOR DECENTRALIZED TESTING MARKETS
VIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
IX. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujifilm Wako
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
QuidelOrtho
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher
